2.16

0.93% 0.02

Pre-market: 2.23 0.07 +3.24%

Novabay Pharmaceuticals Inc (NBY)

Overview News Price History Discussions Forecast Stock Split

Novabay Pharmaceuticals Inc stock is traded at $2.16, with a volume of 309.56K. It is up +0.93% in the last 24 hours and up +137.34% over the past month. NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.

Previous Close:

$2.14

Open:

$2.1

24h Volume:

309.56K

Relative Volume:

0.05

Market Cap:

$12.58M

Revenue:

$14.64M

Net Income/Loss:

$-13.74M

P/E Ratio:

-0.2971

EPS:

-7.27

Net Cash Flow:

$-5.04M

1W Performance:

+23.43%

1M Performance:

+137.34%

6M Performance:

+248.39%

1Y Performance:

+206.38%

1-Day Range:

$2.10

$2.28

1-Week Range:

$1.74

$2.28

52-Week Range:

$0.46

$4.44

Novabay Pharmaceuticals Inc Stock (NBY) Company Profile

Name

Novabay Pharmaceuticals Inc

Sector

Healthcare (1150)

Industry

Biotechnology (643)

Phone

510-899-8800

Address

2000 Powell Street, Suite 1150, Emeryville, CA

Employee

Twitter

@NovaBayPharma

Next Earnings Date

2024-11-07

Latest SEC Filings

NBY's Discussions on Twitter

Compare NBY with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NBY Novabay Pharmaceuticals Inc	2.16	12.46M	14.64M	-13.74M	-5.04M	-7.27
VRTX Vertex Pharmaceuticals Inc	376.62	97.36B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	576.98	60.19B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	458.37	59.56B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	729.76	44.94B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	329.84	36.14B	3.81B	-644.79M	-669.77M	-6.24

Novabay Pharmaceuticals Inc Stock (NBY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-18-19	Initiated	Ladenburg Thalmann	Buy
Jul-06-18	Reiterated	H.C. Wainwright	Buy
Nov-15-17	Reiterated	Laidlaw	Buy
Jun-05-17	Initiated	ROTH Capital	Buy
Mar-27-17	Initiated	Laidlaw	Buy
Feb-06-17	Initiated	Rodman & Renshaw	Buy
Mar-07-16	Downgrade	Maxim Group	Buy → Hold
Dec-14-15	Reiterated	Maxim Group	Buy
Apr-30-15	Resumed	Maxim Group	Buy
Mar-06-13	Initiated	Ascendiant Capital Markets	Strong Buy
Jan-03-08	Initiated	Dawson James	Speculative Buy

View All

Novabay Pharmaceuticals Inc Stock (NBY) Latest News

Sep 24, 2025

How to read the order book for NovaBay Pharmaceuticals Inc.Day Trade & Real-Time Price Movement Reports - newser.com

Sep 24, 2025

Sep 23, 2025